Select your country or region to view content specific to your country.
Anyplex™Ⅱ HPV HR Detection simultaneously detects, differentiates and quantifies 14 high-risk HPV genotypes including HPV16 and HPV18 which are implicated as major risk factors for cervical cancer. Based on Seegene’s proprietary DPO™ and TOCE™ technologies, this assay performs on multiplex real-time PCR instrument and enables accurate screening test of HPV infection in a single reaction.
Detection of 14 high-risk HPV genotypes in a single reaction
Convenient workflow using Seegene’s automated one platform
Quantitative analysis by cyclic-CMTA
Utilization of the UDG system to prevent carry-over contamination
Multiplex real-time PCR with high sensitivity and specificity by utilization of DPO™ and TOCE™ technologies
Automated data interpretation and LIS interlocking with Seegene Viewer
Assistant of appropriate treatment and management for co-infection
Whole process validation from extraction to PCR by whole process control
Useful tool for surveillance and infection control
The result represents co-infection that HPV 16 is low (+) in the HEX channel, HPV 18 is intermediate (++) in the Quasar 670 channel.
- 2020 list of human papillomavirus assays suitable for primary cervical cancer screening
- A comparison of cotton and flocked swabs for vaginal self-sample collection
- Clinical Validation of Anyplex II HPV HR Detection Test for Cervical Cancer Screening in Korea
- Clincal validation of the Anyplex II HPV HR Detection for the Cervical Cancer Screening